Currently, KRAS4A, the unique palmitoylation-depalmitoylation cycle of the RAS isoform, is known to colocalize with HK1 on the outer mitochondrial membrane, and HK1, as a downstream effector of KRAS4A, can enhance glycolytic flux and cancer progression. Here, KRAS is linked to cancer.